Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.42 |
| ▸ | SMO | Q99835 | 4/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16595434 | 0.86 | EPHX2 (0.46) | EPHX2PPARGEGFRERBB2HDAC2 | |
| SCHEMBL6840422 | 0.84 | P2RY14 (0.47) | EPHX2PPARGEGFRERBB2HDAC2 | |
| SCHEMBL23632579 | 0.84 | CYP11B1 (0.56) | EPHX2PPARGEGFRERBB2HDAC2 | |
| SCHEMBL698761 | 0.83 | EPHX2 (0.47) | EPHX2PPARGHDAC2HDAC1SMO | |
| SCHEMBL30614175 | 0.83 | EPHX2 (0.47) | EPHX2PPARGHDAC2HDAC1SMO | |
| SCHEMBL6840266 | 0.82 | HDAC2 (0.45) | EPHX2PPARGEGFRERBB2HDAC2 | |
| SCHEMBL696977 | 0.82 | EGFR (0.52) | EGFRERBB2HDAC2 | |
| SCHEMBL25408602 | 0.79 | EPHX2 (0.50) | EPHX2PPARGEGFRERBB2HDAC2 | |
| SCHEMBL30614188 | 0.79 | BRD4 (0.51) | BRD4CYP11B1CYP11B2 | |
| SCHEMBL25413272 | 0.79 | BRD4 (0.51) | BRD4CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3912977-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BioMarin Pharmaceutical Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3046920-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-10927092-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARM INC (US) | 2021-02-23 | — | — | US | disclosed |
| US-20190263775-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2019-08-29 | — | — | US | disclosed |
| US-10227323-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| WO-2015042397-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927092-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | EPHX2 960/4885PPARG 828/4885EGFR 4072/4885 |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | EPHX2 960/4885PPARG 828/4885EGFR 4072/4885 |
| US-10227323-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | EPHX2 960/4885PPARG 828/4885EGFR 4072/4885 |
| US-20190263775-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | EPHX2 960/4885PPARG 828/4885EGFR 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.